EUCTR2012-002920-33-IT进行中（未招募）不适用
A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
CERUS CORPORATIO0 个研究点开始时间: 2012年10月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age >= 10 years, of either gender - Diagnosed with thalassemia major and currently participating in a chronic transfusion program - At least a one year history of chronic RBC transfusion support with a stable transfusion requirement (per treating physician) - Intervals of at least 14 days between RBC transfusions - All RBC components are given on one day for each transfusion episode - Negative direct antiglobulin tests (DAT) - Stable iron chelation regimen - Available for measurement of hemoglobin level at one hour post transfusion - Signed and dated informed consent form
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 35
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Baseline antibody specific to S-303 treated RBC (positive test, as defined in Section 8.4.1) - Evidence of splenic hyper function defined as a transfusion requirement >180 cc/kg/year (at 100% hematocrit) - Splenic enlargement: spleen palpable =4 cm below costal margin - Alloimmunization to minor blood group antigens to the extent that the ready provision of compatible blood may not be feasible for the study (alloimmunization alone is not an automatic exclusion) - Current specialized treatment with washed or frozen RBC Requirement for gamma irradiated RBC components (would present blinding difficulty due to blood component labeling regulations - Treatment with any medication that is known to adversely affect RBC viability - HIV or HCV infection (defined as RNA positive) - Pregnant or breast feeding female, or female of child-bearing potential not using a medically approved form of contraception - Acute or chronic medical disorder other than thalassemia that, in the opinion of the Investigator or medical monitor, may prevent the subject from completing participation in the study - Participation in another clinical study, either concurrently or within the previous 28 days, in which the study drug or device may influence red blood cell viability
研究者
相似试验
进行中（未招募）
1 期
A Randomized Controlled Study to Evaluate Efficacy and Safety of INTERCEPT Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC TransfusioThalassemia MajorMedDRA version: 18.0Level: LLTClassification code 10054661Term: Thalassemia majorSystem Organ Class: 100000004850EUCTR2012-002920-33-GBCerus Corporation86
尚未招募
不适用
To evaluate the effect and tolerance of a plant based diet in reducing the flare of clinical symptoms in patients with ulcerative colitis who are asymptomatic at time of studyCTRI/2022/03/041032AIIMS
尚未招募
2 期
Testing Parasternal Intercostal Block for Pain Relief After Heart Surgery at SMS Hospital, JaipurCTRI/2024/06/068774Sawai Mansingh Medical College and Hospital
招募中
不适用
Curative effect evaluation of traditional Chinese medicine bloodletting cupping for treating herpes zoster neuralgia and occurrence of sequelae neuralgiaHerpes zosterITMCTR2100004849Beijing Friendship Hospital, Capital Medical University
尚未招募
2 期
Study to assess effect of Ayurvedic drugs on Recurrent Allergic conjunctivitisCTRI/2023/07/055497ational Institute of Ayurveda Deemed to be University Jaipur